NewsRoom

Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013

20122011201020092008

Feb 7, 2019
-- MEI Remains in Strong Position as ME-401 Advances to Global Phase 2 Study to Support FDA Accelerated Approval --
Dec 2, 2018
- Data Support Complementary Potential of Intermittent and Continuous Dosing Schedules as Means to Optimize Clinical Risk-Benefit Ratio in Relapsed/Refractory Follicular Lymphoma Patients -
Nov 8, 2018
-- MEI on Track to Initiate ME-401 Phase 2 Accelerated Approval Study Around Year-End --
Nov 5, 2018
MEI to Receive $10 Million Upfront Payment, Plus Milestones and Tiered Royalty Payments
Aug 30, 2018
-Fiscal Year 2018 Highlighted by Progress Across All Four Clinical-stage Oncology Candidates; ME-401 Accelerated Approval Study to Start by Year-end 2018-
 

rss